Literature DB >> 2664171

Uveitis and arthritis induced by adjuvant: clinical, immunologic and histologic characteristics.

R E Petty1, W Johnston, A Q McCormick, D W Hunt, J Rootman, D F Rollins.   

Abstract

The intradermal administration of complete Freund's adjuvant (CFA) containing Mycobacterium butyricum to Sprague-Dawley (SD) and Lewis strain rats results in polyarthritis and uveitis. Over 90% of the eyes examined from the SD rats given CFA had histologic evidence of anterior uveitis, clinically evident in only 20 to 28%. Many rats developed arthritis without clinical uveitis, but uveitis was rare in the absence of arthritis. Histologically, the ocular inflammation was characterized by a polymorphonuclear, and later, a lymphocytic infiltration of the iris and ciliary body with cells and fibrinous exudate in the anterior chamber and cells in the vitreous. Antibodies and cellular immunity to ocular (S antigen, alpha crystallin), articular (type II collagen, proteoglycan) and bacterial components (MDP), were demonstrated in some rats, but positive tests did not correlate with either articular or ocular disease. Ten percent of rats given type II collagen in incomplete Freund's adjuvant developed uveitis. Thus, the pathogenesis of the arthritis and uveitis in the adjuvant model may be mediated by lymphocytes which exhibit crossreactivity with antigens in these structures, although the specificity of such antigens has not been identified in our studies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2664171

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Interplay between innate and adaptive immunity in the development of non-infectious uveitis.

Authors:  François Willermain; James T Rosenbaum; Bahram Bodaghi; Holly L Rosenzweig; Sarah Childers; Travis Behrend; Gerhild Wildner; Andrew D Dick
Journal:  Prog Retin Eye Res       Date:  2011-11-22       Impact factor: 21.198

Review 2.  Juvenile chronic arthritis, chronic iridocyclitis, and reactivity to histones.

Authors:  A M Leak; P Woo
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

Review 3.  The Eyes Have it: A Rheumatologist's View of Uveitis.

Authors:  James T Rosenbaum; Andrew D Dick
Journal:  Arthritis Rheumatol       Date:  2018-08-23       Impact factor: 10.995

Review 4.  The eye in spondyloarthritis.

Authors:  James T Rosenbaum
Journal:  Semin Arthritis Rheum       Date:  2019-12       Impact factor: 5.532

5.  The role of TLR4 activation in photoreceptor mitochondrial oxidative stress.

Authors:  MinHee K Ko; Sindhu Saraswathy; Jignesh G Parikh; Narsing A Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

6.  Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts.

Authors:  Rebecca L Sheets; Judith Stein; T Scott Manetz; Charla Andrews; Robert Bailer; John Rathmann; Phillip L Gomez
Journal:  Toxicol Sci       Date:  2006-03-28       Impact factor: 4.849

7.  Spondyloarthritis: the eyes have it: uveitis in patients with spondyloarthritis.

Authors:  James T Rosenbaum; Holly L Rosenzweig
Journal:  Nat Rev Rheumatol       Date:  2012-04-03       Impact factor: 20.543

Review 8.  [Uveitis in conjunction with rheumatological diseases in childhood].

Authors:  C Sengler; R Keitzer; U Pleyer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

9.  In vivo lymphokine production in experimental autoimmune uveoretinitis.

Authors:  D G Charteris; S L Lightman
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

10.  Heat shock protein peptides reactive in patients with Behçet's disease are uveitogenic in Lewis rats.

Authors:  M R Stanford; E Kasp; R Whiston; A Hasan; S Todryk; T Shinnick; Y Mizushima; D C Dumonde; R van der Zee; T Lehner
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.